By the Top Tier Newswire AI Desk · September 10, 2026 at 9:45 AM ET · reviewed against 2 wire stories
NOVAVAX INC (NVAX) is down -6.75% in the latest session. Our newswire has captured 2 stories on NVAX across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 49/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
NVAX stock is down 6.75% at $9.19 as of the latest trade. The decline follows a weak intraday performance and deteriorating investor sentiment. The stock opened at $9.85 but quickly reversed course, hitting a session low of $9.12 before stabilizing slightly. The move comes amid a broader trend of underperformance relative to peers and a challenging fundamental backdrop.
What Happened
Novavax Inc. stock has fallen sharply in the session, with the stock opening near $9.85 and quickly trending downward. The stock has struggled to hold above $9.50 throughout the morning, with a session low reached at $9.12. The stock has traded at a volume of 0.8 million shares, which is 0.2 times the 3-month average, suggesting limited participation in the move. The decline is part of a broader pattern of weakness, with the stock printing four fresh 52-week lows on September 10. The stock has also been under pressure in the 30 days, with sentiment dropping from an average of 60 to 49 in the last week. Meanwhile, the company is scheduled to present at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, but no material developments from that event appear to have influenced today’s action.
What The Data Shows
The stock has traded in a wide range this year, from $6.20 to $11.97, and currently sits near the lower end of that range. The company remains unprofitable with a trailing twelve-month net margin of -59.9% and a revenue decline of 61.6% year-to-date. The stock has a beta of 2.45, making it highly volatile compared to the broader market. The recent underperformance is also reflected in the intraday session shape, with the stock unable to maintain early gains and showing a steep decline in the first two hours of trading.
What To Watch
Investors should monitor the company’s presentation at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, for any new developments or guidance that could influence the stock’s trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
NVAX · Sep 10 session (5-min) · -6.40% vs prior close · updated 8:48 PM ETAI sentiment, last 36h · averaged over 2 stories · 49/100 neutral
The headlines behind the move
Story flow · 2 stories on the wire, last 36h · hover or tap a dot for the headline
3d agoMarketWatchBEARISH 42General
Novavax Inc. stock underperforms Wednesday when compared to competitors
3d agoSeeking AlphaBULLISH 56General
Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Novavax, Inc. (NVAX) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 9, 2026 9:45 AM EDTCompany ParticipantsJohn Jacobs - President,...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →